H. Spiridonidis

2.7k citations
8 papers · 2.1k · 1 hit paper · h-index 4

Impact in

  • Oncology top 1%
    • Colorectal Cancer Treatments and Studies
    • HER2/EGFR in Cancer Research
    • Lung Cancer Research Studies
    • Lung Cancer Treatments and Mutations
    • Lung Cancer Diagnosis and Treatment
    • Gastric Cancer Management and Outcomes

Papers in

    • Lung Cancer Treatments and Mutations 5
    • Lung Cancer Diagnosis and Treatment 1
    • Prostate Cancer Treatment and Research 1
    • Cancer Treatment and Pharmacology 2
    • Colorectal Cancer Treatments and Studies 2
    • HER2/EGFR in Cancer Research 2
    • Neutropenia and Cancer Infections 2

H. Spiridonidis

8 papers receiving 2.1k citations

H. Spiridonidis's Hit Papers

Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non–Small Cell Lung Cancer 2003 · 2.1k citations
2.1k0+7+15Years since publication50010001.5k2.0k

Peers

H. Spiridonidis
Comparison fields: 5 of 73
  • Oncology 1.7k
  • Pulmonary and Respiratory Medicine 1.8k
  • Cancer Research 288
  • Molecular Biology 541
  • Genetics 75
Replace Ira A. Oliff with:
Ira A. Oliff United States
Daniel T. Milton United States
Toshiyuki Kozuki Japan
Purvish Parikh India
Kristine Pemberton United Kingdom
V. A. Miller United States
Jean-Claude Cutz Canada
L. Fehrenbacher United States
Carmelo Tibaldi Italy
Motoko Tachihara Japan
H. Spiridonidis relative to Ira A. Oliff United States Ira A. Oliff's profile →
Citations per field
00.5×1.5×
Ira A. Oliff · 1×
Citations per year

Countries citing papers authored by H. Spiridonidis

Since Specialization
Citations

This map shows the geographic impact of H. Spiridonidis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by H. Spiridonidis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites H. Spiridonidis more than expected).

Fields of papers citing papers by H. Spiridonidis

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by H. Spiridonidis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by H. Spiridonidis. The network helps show where H. Spiridonidis may publish in the future.

Co-authors

The 25 scholars most cited alongside H. Spiridonidis, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with H. Spiridonidis Line = papers co-authored together H. Spiridonidis links everyone, so they are left out of the graph.

All Works

8 of 8 papers shown
#Work
1
Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non–Small Cell Lung Cancer
Hit paper breakdown →
20032119
2
Efficacy and safety of gefitinib (Iressa, ZD1839), an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with advanced non-small cell lung cancer
200311
3 20104
4 20043
5
Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non-Small Cell Lung Cancer
20173
6 20042
7 20041
8 20041

About H. Spiridonidis

H. Spiridonidis is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Organic Chemistry, Genetics and Cancer Research, having authored 8 papers that have together received 2.1k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (5 papers), Cancer Treatment and Pharmacology (2 papers), Colorectal Cancer Treatments and Studies (2 papers), HER2/EGFR in Cancer Research (2 papers), Neutropenia and Cancer Infections (2 papers), Cancer Genomics and Diagnostics (1 paper), Lung Cancer Diagnosis and Treatment (1 paper) and Prostate Cancer Treatment and Research (1 paper). The work is most often cited by research in Oncology (1.7k citations), Pulmonary and Respiratory Medicine (1.8k citations), Cancer Research (288 citations), Molecular Biology (541 citations) and Genetics (75 citations). H. Spiridonidis has collaborated with scholars based in United States, Australia and Canada. Frequent co-authors include Diane Prager, Chandra P. Belani, Joan H. Schiller, Ronald B. Natale, Kathy S. Albain, Karen Kelly, David Cella, Michael Wolf, Steven D. Averbuch and Alan Sandler. Their work appears in journals such as Journal of Clinical Oncology, JAMA and Asia-Pacific Journal of Clinical Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact